206 related articles for article (PubMed ID: 10613661)
1. Reactivity of soluble fibrin assays with plasmic degradation products of fibrin and in patients receiving fibrinolytic therapy.
McCarron BI; Marder VJ; Francis CW
Thromb Haemost; 1999 Dec; 82(6):1722-9. PubMed ID: 10613661
[TBL] [Abstract][Full Text] [Related]
2. The role of soluble cross-linked fibrin in D dimer immunoreactivity of plasmic digests.
Brenner B; Francis CW; Marder VJ
J Lab Clin Med; 1989 Jun; 113(6):682-8. PubMed ID: 2732616
[TBL] [Abstract][Full Text] [Related]
3. Fibrin degradation products, fibrin monomer and soluble fibrin in disseminated intravascular coagulation.
Horan JT; Francis CW
Semin Thromb Hemost; 2001 Dec; 27(6):657-66. PubMed ID: 11740689
[TBL] [Abstract][Full Text] [Related]
4. The use of soluble fibrin in evaluating the acute and chronic hypercoagulable state.
Dempfle CE
Thromb Haemost; 1999 Aug; 82(2):673-83. PubMed ID: 10605767
[TBL] [Abstract][Full Text] [Related]
5. Validation, calibration, and specificity of quantitative D-dimer assays.
Dempfle CE
Semin Vasc Med; 2005 Nov; 5(4):315-20. PubMed ID: 16302152
[TBL] [Abstract][Full Text] [Related]
6. The fibrin assay comparison trial (FACT): correlation of soluble fibrin assays with D-dimer.
Dempfle CE; Zips S; Ergül H; Heene DL;
Thromb Haemost; 2001 Nov; 86(5):1204-9. PubMed ID: 11816708
[TBL] [Abstract][Full Text] [Related]
7. The detection of D-dimer in plasma by enzyme immunoassay: improved discrimination is obtained with a more specific signal antibody.
Hart R; Bate I; Dinh D; Elms M; Bundesen P; Hillyard C; Rylatt DB
Blood Coagul Fibrinolysis; 1994 Apr; 5(2):227-32. PubMed ID: 7519890
[TBL] [Abstract][Full Text] [Related]
8. The monoclonal antibody that recognizes an epitope in the C-terminal region of the fibrinogen alpha-chain reacts with soluble fibrin and fibrin monomer generated by thrombin but not with those formed as plasmin degradation products.
Suzuki A; Ebinuma H; Matsuo M; Miyazaki O; Yago H
Thromb Res; 2007; 121(3):377-85. PubMed ID: 17561232
[TBL] [Abstract][Full Text] [Related]
9. [Evaluation of novel assays for the detection of crosslinked fibrin degradation products in whole blood by the agglutination of the red blood cells].
Kuroso K; Isogai N; Koike K; Fukutake K; Fujimaki M
Rinsho Byori; 1992 Dec; 40(12):1281-6. PubMed ID: 1307633
[TBL] [Abstract][Full Text] [Related]
10. A molecular model of plasmic degradation of crosslinked fibrin.
Francis CW; Marder VJ
Semin Thromb Hemost; 1982 Jan; 8(1):25-35. PubMed ID: 6460319
[TBL] [Abstract][Full Text] [Related]
11. Lymphocyte suppressive peptides from fibrinogen are derived predominantly from the A alpha chain.
Plow EF; Edgington TS
J Immunol; 1986 Sep; 137(6):1910-5. PubMed ID: 2943807
[TBL] [Abstract][Full Text] [Related]
12. [Clinical significance of a new fibrinogen/fibrin degradation products(FDP) test using plasma samples for the diagnosis of fibrinogenolysis and fibrinolysis].
Imoto K; Yasumuro Y; Taki M; Suzuki N; Tanabe H; Ichikawa Y
Rinsho Byori; 2001 Mar; 49(3):283-9. PubMed ID: 11307330
[TBL] [Abstract][Full Text] [Related]
13. The Fibrin Assay Comparison Trial (FACT): evaluation of 23 quantitative D-dimer assays as basis for the development of D-dimer calibrators. FACT study group.
Dempfle CE; Zips S; Ergül H; Heene DL;
Thromb Haemost; 2001 Apr; 85(4):671-8. PubMed ID: 11341504
[TBL] [Abstract][Full Text] [Related]
14. [Changes of blood coagulative and fibrinolytic system and function of pulmonary vascular endothelium after therapy in patients with acute pulmonary thromboembolism].
Pang BS; Wang C; Lu Y; Yang YH; Xing GH; Mao YL; Huang XX; Zhai ZG
Zhonghua Yi Xue Za Zhi; 2007 Nov; 87(43):3074-8. PubMed ID: 18261355
[TBL] [Abstract][Full Text] [Related]
15. Measurement of crosslinked fibrin degradation products - an immunoassay using monoclonal antibodies.
Elms MJ; Bunce IH; Bundesen PG; Rylatt DB; Webber AJ; Masci PP; Whitaker AN
Thromb Haemost; 1983 Aug; 50(2):591-4. PubMed ID: 6356456
[TBL] [Abstract][Full Text] [Related]
16. Binding of a new monoclonal antibody against N-terminal heptapeptide of fibrin alpha-chain to fibrin polymerization site 'A': effects of fibrinogen and fibrinogen derivatives, and pretreatment of samples with NaSCN.
Dempfle CE; Dollman M; Lill H; Puzzovio D; Dessauer A; Heene DL
Blood Coagul Fibrinolysis; 1993 Feb; 4(1):79-86. PubMed ID: 8457657
[TBL] [Abstract][Full Text] [Related]
17. Immunochemical discrimination of leukocyte elastase from plasmic degradation products of fibrinogen.
Plow EF; Gramse M; Havemann K
J Lab Clin Med; 1983 Dec; 102(6):858-69. PubMed ID: 6227673
[TBL] [Abstract][Full Text] [Related]
18. Specific identification of fibrin polymers, fibrinogen degradation products, and crosslinked fibrin degradation products in plasma and serum with a new sensitive technique.
Connaghan DG; Francis CW; Lane DA; Marder VJ
Blood; 1985 Mar; 65(3):589-97. PubMed ID: 3971042
[TBL] [Abstract][Full Text] [Related]
19. [A novel molecular marker for thrombus formation and life prognosis--clinical usefulness of measurement of soluble fibrin monomer-fibrinogen complex (SF)].
Koga S
Rinsho Byori; 2004 Apr; 52(4):355-61. PubMed ID: 15164605
[TBL] [Abstract][Full Text] [Related]
20. Comparison of immunological and functional assays for measurement of soluble fibrin.
Dempfle CE; Pfitzner SA; Dollman M; Huck K; Stehle G; Heene DL
Thromb Haemost; 1995 Aug; 74(2):673-9. PubMed ID: 8585005
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
